On Thursday, Adar Poonawalla, CEO, Serum Institute of India (SII), said that developing a vaccine is like a rollercoaster ride with ups and downs. “Developing a vaccine is like riding a rollercoaster; there are plenty of ups and downs. Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed,” Poonawalla said in a tweet.
Developing a vaccine is like riding a rollercoaster; there are plenty of ups and downs. Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed.https://t.co/8oMvMhklvU
— Adar Poonawalla (@adarpoonawalla) May 21, 2020
Serum Institute of India (SII), one of the strong candidates for a potential COVID-19 vaccine tested by researchers at Oxford University failed to protect monkeys from being infected by the virus but on a positive side, the potential vaccine helped to protect the monkeys from pneumonia.
After observing the reports of the Oxford vaccine’s performance on monkeys, researchers triggered to test the vaccine’s potency in humans. The Serum Institute is all set with the plan to manufacture four to five million doses in India. It is one of seven global companies that will manufacture the vaccine being developed by the Oxford Vaccine Group.
On April 27, one of the largest producers of vaccines Serum Institute of India (SII) disclosed that it will soon work on the production of COVID-19 vaccine within 2-3 weeks, developed by Oxford University. The firm assured that if clinical trials of the vaccine are successful then they the COVID-19 vaccine will be out in the market by October. More than 800 healthy volunteers injected with ChAdOx1 nCoV-19 for the study.
